Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Weise Discusses Challenges With Biosimilar Acceptance in Oncology

Martina Weise, MD
Published: Thursday, Oct 25, 2018



Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses challenges with biosimilar acceptance in oncology.

When supportive care biosimilars entered the oncology landscape over 10 years ago, they were met with some skepticism, says Weise. This skepticism is echoed today, as biosimilars for biologics such as trastuzumab (Herceptin) and bevacizumab (Avastin) are awaiting use in the United States. As time has progressed, there has been more understanding as to the regulatory procedure for approving biosimilars, as well as the benefit that they offer.

Not only do biosimilars create competition in the marketplace, but they also offer the opportunity for patients in countries that cannot be offered biologics to receive care, says Weise. She adds that in Eastern European countries that previously had not had access to biologics are now experiencing an increase in the use of biosimilars for the support and treatment of patients with cancer.


Martina Weise, MD, head of Division Licensing 2, and German CHMP member of the Federal Institute for Drugs and Medical Devices, discusses challenges with biosimilar acceptance in oncology.

When supportive care biosimilars entered the oncology landscape over 10 years ago, they were met with some skepticism, says Weise. This skepticism is echoed today, as biosimilars for biologics such as trastuzumab (Herceptin) and bevacizumab (Avastin) are awaiting use in the United States. As time has progressed, there has been more understanding as to the regulatory procedure for approving biosimilars, as well as the benefit that they offer.

Not only do biosimilars create competition in the marketplace, but they also offer the opportunity for patients in countries that cannot be offered biologics to receive care, says Weise. She adds that in Eastern European countries that previously had not had access to biologics are now experiencing an increase in the use of biosimilars for the support and treatment of patients with cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advent of Oncology Monoclonal Antibody Biosimilars ‒ A European Perspective OnlineNov 30, 20183.0
Community Practice Connections™: Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic MalignanciesMar 08, 20193.0
Publication Bottom Border
Border Publication
x